With its eyes set on an IPO raise, InCarda unrolls mid-stage data backing inhaled arrhythmia drug

Working to craft an old arrythmia drug into a more user-friendly inhaled formulation, InCarda is expecting to use new Phase II data revealed Wednesday as the foundation of a potential IPO raise.

The program, repurposing the oral and IV drug flecainide into an inhalant, completed the latest cohort of its...

Click to view original post